Table 1.
Characteristics of Patients and Indications for Isavuconazole Prophylaxis
| Characteristic | No. (%) |
|---|---|
| Total No. of patients | 145 |
| Age, y, median (range) | 60 (19–85) |
| Sex, No. (%) | |
| Male | 70 (48.3) |
| Female | 75 (51.7) |
| Total courses, No. | 197 |
| Duration of prophylaxis, days, median (IQR) | 22 (15–54) |
| Indications for prophylaxis, No. (% of total courses) | |
| De novo AML | 54 (27.4) |
| Induction | 38 |
| Consolidation | 15 |
| Othera | 1 |
| Relapsed/refractory AML | 60 (30.5) |
| Reinduction/salvage | 50 |
| Consolidation | 6 |
| Otherb | 4 |
| Miscellaneous HMc, No. (% of total courses) | 20 (10.1) |
| Post-HCT, No. (% of total courses) | 63 (32) |
| High-dose steroid used | 44 |
| Prolonged pre-HCT neutropenia | 19 |
Abbreviations: AML, acute myeloid leukemia; HCT, hematopoietic cell transplant; HM, hematologic malignancy; IQR, interquartile range.
aDonor lymphocyte infusion.
bDecitabine, azacitidine, hydroxyurea.
cMyelodysplastic syndrome (8), acute promyelocytic leukemia (2), acute lymphoblastic leukemia (3), aplastic anemia (5), chronic myelogenous leukemia (1), chronic lymphocytic leukemia (1).
dGraft-vs-host disease (40), idiopathic pneumonitis syndrome (1), diffuse alveolar hemorrhage (1), bronchiolitis obliterans (2).